Chugai Pharmaceutical Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Chugai Pharmaceutical Stock Forecast and Price Target
The average target price for Chugai Pharmaceutical's stock set by renowned analysts in recent months is ¥6150.00, representing a potential upside of approximately 26.54% from its last closing price if met by 2025. This estimation is based on a high estimate of ¥7410.00 and a low estimate of ¥4500.00. If you are interested in 4519 stock, it is important to also consider its competitors.
26.54% Upside
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$724.87 | Buy/Sell | $636.99 | 15.54% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.82 | Buy/Sell | $174.55 | 15.79% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.29 | Buy/Sell | $178.42 | 12.98% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£120.26 | Buy/Sell | £165.99 | 34.72% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF218.80 | Buy/Sell | CHF307.83 | 24.54% |
Chugai Pharmaceutical Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Chugai Pharmaceutical's Revenue has grown by 41.23%, rising from ¥786.95B to ¥1.11T. In the following year, the 0 analysts surveyed believe that Chugai Pharmaceutical's Revenue will decrease by 9.52%, reaching ¥1.01T. According to professionals, by 2030, Chugai Pharmaceutical's Revenue will have decreased by 4.06%, falling down to ¥1.07T.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.26 | Buy/Sell | $32.87 | 20.74% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.62€ | Buy/Sell | 102.80€ | 18.97% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.70 | Buy/Sell | $58.15 | 21.92% |
.jpg)
Chugai Pharmaceutical Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Chugai Pharmaceutical's Dividend per Share has grown, rising from ¥55.00 to ¥80.00 – a growth of 45.45%. The next year, 0 experts forecast that Chugai Pharmaceutical's Dividend per Share will decrease by 10.90%, reaching ¥71.28. In 2030, professionals predict that Chugai Pharmaceutical's Dividend per Share will decrease by 6.97%, reaching ¥74.42.
Chugai Pharmaceutical EBITDA Forecast for 2023 - 2025 - 2030
Chugai Pharmaceutical's EBITDA has seen impressive growth In the last three years, rising from ¥331.61B to ¥470.91B – a growth of 42.01%. For the next year, 0 analysts project Chugai Pharmaceutical's EBITDA to drop by 8.89%, reaching ¥429.05B. By 2030, professionals believe that Chugai Pharmaceutical's EBITDA will decrease by 1.24%, reaching ¥465.06B – a concerning trend for the company.
Chugai Pharmaceutical EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Chugai Pharmaceutical's EBIT has grown by 45.79%, rising from ¥301.23B to ¥439.17B. According to 0 prominent analysts, Chugai Pharmaceutical's EBIT will fall by 9.35% in the next year, reaching ¥398.10B. By 2030, professionals believe that Chugai Pharmaceutical's EBIT will decrease by 1.14%, reaching ¥434.15B – a concerning trend for the company.
Site Navigation
.jpg)